AtriCure (ATRC) Advances Key Heart Disease Trial 12 Months Ahead of Schedule

AtriCure, Inc. (NASDAQ:ATRC) is one of the top small cap stocks with huge growth potential. On May 6, Needham reiterated its Buy rating and $45 price target on AtriCure, Inc. (NASDAQ:ATRC) after the company delivered blowout Q1 2026 earnings.

AtriCure (ATRC): A Key Heart Disease Trial Just Moved 12 Months Ahead of Schedule

AtriCure shared the earnings on May 5 and reported quarterly worldwide revenue of $141.2 million, a 14.3% jump year over year. This figure exceeded the analyst consensus estimate by about 1.4%. Mike Carrel, President and CEO, explained on the earnings call that this beat was made possible by a 28% growth in the pain management segment. This growth came on the back of the cryoSPHERE MAX probe. Other drivers the CEO pointed to are growth in the appendage management segment and open ablation.

Needham acknowledged the performance but noted that the key highlight that caught their attention was the accelerated timeline on the BoxX-NoAF clinical trial. This is a study testing a minimally invasive procedure to treat atrial fibrillation. AtriCure now expects patient enrollment to be complete by the end of this year, which is a whole 12 months ahead of its prior plan. This also means the trial results could be available in 2027 instead of 2028. For Needham, this is a major development because a positive data readout could unlock a major new market opportunity for AtriCure.

AtriCure, Inc. (NASDAQ:ATRC) is a medical device company. It develops technologies for the treatment of atrial fibrillation and related cardiac conditions. Its products include ablation systems, surgical devices, and appendage management technologies used by cardiac surgeons and electrophysiologists worldwide.

While we acknowledge the risk and potential of ATRC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ATRC and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Renaissance Technologies Returns, AUM, CEO and Top 10 Semiconductor Stock Picks and Top 10 Stocks to Buy for Long Term.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1